<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="89106">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01998152</url>
  </required_header>
  <id_info>
    <org_study_id>2013230</org_study_id>
    <nct_id>NCT01998152</nct_id>
  </id_info>
  <brief_title>Individualized Nutritional Counselling During Chemotherapy for Colorectal Cancer (COLONUT)</brief_title>
  <acronym>COLONUT</acronym>
  <official_title>The Effect of Individualized NUTritional Counselling on Muscle Mass and Treatment Outcome in Patients With Metastatic COLOrectal Cancer Undergoing Chemotherapy: the COLONUT Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to study the effect of individualized nutritional counselling compared to
      usual nutritional care on cross-sectional muscle area in patients with stage IV colorectal
      cancer during palliative chemotherapy. Secondary, effect on total lean body mass, treatment
      intensity, physical functioning, quality of life and survival will be studied.We hypothesize
      that patients in the intervention arm benefit from individualized nutritional counseling.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2013</start_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in skeletal muscle area (cm2)between individualized nutritional counselling versus usual nutritional care</measure>
    <time_frame>During 9 weeks of palliative chemotherapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>will be measured with SliceOmatic software V5.0 (Tomovision) with use of routinely conducted CT scans for diagnostic and disease evaluation purposes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in total body lean body mass and segmental lean body mass (DEXA) in patients with stage IV colorectal cancer during 9 weeks of palliative chemotherapy between individualized nutritional counselling versus usual nutritional care</measure>
    <time_frame>During 9 weeks of palliative chemotherapy</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in skeletal muscle area in patients with stage IV colorectal cancer during 20 weeks of palliative chemotherapy between individualized nutritional counselling.versus ususal nutritional care.</measure>
    <time_frame>During 20 weeks of palliative chemotherapy</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of treatment toxicity, treatment intensity, treatment outcome, survival, physical functioning, quality of life and handgrip strength of both study arms</measure>
    <time_frame>During 9 weeks and during 20 weeks of palliative chemotherapy</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Associations of (changes in) muscle area with (changes in) mid-upper arm muscle circumference, whole body fat free mass (BIA) and whole body lean body mass (DEXA).</measure>
    <time_frame>During 9 weeks of palliative chemotherapy</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Advanced or Recurrent Colorectal Cancer, Stage IV</condition>
  <arm_group>
    <arm_group_label>Nutritional counseling</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individualized nutritional counselling by a registered dietitian</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual nutritional care by the oncologist. A dietitian is only involved when serious nutritional problems occur.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Nutrional counseling</intervention_name>
    <description>Patients in the intervention-arm will receive individualized nutritional counselling by a registered dietitian during standard treatment with chemotherapy. The main goals of the nutritional intervention will be to enable every patient to achieve sufficient protein and energy intake with attention for sufficient intake of micronutrients and a sufficient physical activity level.</description>
    <arm_group_label>Nutritional counseling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years

          -  Advanced or recurrent colorectal cancer

          -  Scheduled for treatment with first line palliative chemotherapy

          -  Either CAPOX(-B) or FOLFOX(-B)

          -  CT scan suitable for evaluating muscle mass at L3 level

          -  Understanding of the Dutch language

          -  Able and willing to give written informed consent

        Exclusion Criteria:

          -  Prior systemic treatment for metastatic disease

          -  Chemotherapy in the previous six months for non-metastatic disease

          -  WHO performance status ≥ 3

          -  Long-term high dose of corticosteroids: ≥ three weeks ≥ ten milligram prednisolon or
             equivalent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M.A.E van Bokhorst - de van der Schueren, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>VU University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>M.A.E van Bokhorst - de van der Schueren, Dr</last_name>
    <phone>0031-20-4443410</phone>
    <email>m.vanbokhorst@vumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>H.M.W Verheul, MD, PhD</last_name>
    <phone>0031-20-4444321</phone>
    <email>h.verheul@vumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>VU Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>NL-1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>M.A.E van Bokhorst - de van der Schueren, Dr.</last_name>
      <phone>0031-20-4443410</phone>
      <email>m.vanbokhorst@vumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>H.M.W. Verheul, MD, PhD</last_name>
      <phone>0031-20-4444321</phone>
      <email>h.verheul@vumc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>S. Blauwhoff-Buskermolen, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spaarne hospital</name>
      <address>
        <city>Hoofddorp</city>
        <zip>NL-2134 TM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>A. Beeker, Drs.</last_name>
    </contact>
    <investigator>
      <last_name>A. Beeker, Drs.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 22, 2013</lastchanged_date>
  <firstreceived_date>November 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>M.A.E van Bokhorst - de van der Schueren, Dr.</investigator_full_name>
    <investigator_title>Senior Investigator dietetics and nutrition sciences Vumc</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
